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Abstract
Background: There are 350 million carriers of hepatitis B virus (HBV) around the world. HBV can be associated with type II diabetes
mellitus. The aim of this study was to evaluate the prevalence and risk factors for type II diabetes mellitus among patients with HBV.
Methods: This community-based, cross sectional, descriptive, correlational study recruited participants above 13 years, who resided
in Esfandiar rural area, Tabas, Iran. A blood sample was collected from each participant for serological and biochemical tests. A
researcher-made questionnaire was used to collect data on the participants’ demographic characteristics, HBV risk factors, and
diabetes mellitus risk factors. Independent sample t test, Chi square test, and Fisher’s exact test were applied in SPSS v. 22.0 at a
significance level of < 0.05.
Results: This study was conducted on 1245 rural dwellers, with the mean age of 36.5 ± 18.5 years (range, 13 - 96 years). The study
population consisted of 676 (54.3%) males and 569 (45.7%) females. The prevalence of type II diabetes mellitus and hepatitis B sur-
face antigen (HBsAg) seropositivity was 7.6% (n, 95) and 12.5% (n, 156) among the participants, respectively. Moreover, the prevalence
of HBsAg seropositivity among diabetic patients was insignificantly higher than nondiabetic patients (15.8% vs. 12.3%; P = 0.32). The
prevalence of seropositivity among diabetic men was significantly higher than diabetic women (P = 0.02). The mean age, body
mass index, systolic and diastolic blood pressure, waist circumference, and hemoglobin A1c level were significantly higher among
diabetic, antigen-positive patients, compared to their nondiabetic counterparts (P < 0.05). However, these groups were not signifi-
cantly different with respect to alanine aminotransferase and aspartate aminotransferase levels (P > 0.05).
Conclusions: This study suggests that HBV can be a risk factor for type II diabetes mellitus. Therefore, continuous monitoring for
diabetes mellitus is essential for patients with HBV infection, particularly those above 50 years, those with a body mass index above
25 kg/m2, and those with a positive family history of type II diabetes mellitus.
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1. Background
Diabetes mellitus (DM) is one of the most serious sys-
temic diseases around the world. The number of patients
with type II DM was 177 million in 2002, which is estimated
to reach 300 million by 2025 (1). The prevalence of type
II DM is expected to increase by 69% and 20% in develop-
ing and developed countries by 2030, respectively; also, the
number of diabetic patients will reach 24 million in Africa
(2).
On the other hand, hepatitis B virus (HBV) infection is
a serious and debilitating disease. Currently, there are 350
million carriers of HBV around the world (3). Each year, 877
000 people die due to the serious complications of HBV in-
fection, including cirrhosis and hepatocellular carcinoma
(4). The prevalence of HBV infection among Iranians be-
low 22 and 28 years is less than 0.5% and 1%, respectively.
Also, the prevalence of HBV infection is estimated at 1.6% in
Southern Khorasan province, Iran (5), while its prevalence
among adults ranges from 6.3% to 13.1% in this province (6).
Hepatitis and type II DM are interrelated in some ways.
According to previous research, 60% of patients with cir-
rhosis suffer from impaired glucose tolerance, while 20%
have type II DM. On the other hand, diabetic patients expe-
rience a wide range of liver problems from abnormal liver
function to hepatomegaly, hepatic steatosis, and steato-
hepatitis (7). Overall, liver plays a significant role in glucose
homeostasis. Therefore, liver inflammation and degenera-
tion during hepatitis alter glucose metabolism.
Inflammatory mediators, such as tumor necrosis fac-
tor and nitric oxide, cause insulin dysfunction in the liver,
as well as insulin resistance (8). Increased levels of tumor
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necrosis factor suppress tyrosine phosphorylation in in-
sulin receptors and cause insulin resistance (9). The repli-
cation of HBV in pancreatic cells also aggravates insulin
dysfunction (9). On the other hand, insulin resistance,
steatosis, and cytopathic effects of HBV can accelerate hep-
atic fibrosis (8).
The association of type II DM with hepatitis has been
reported in different studies. In this regard, a study on
3377 individuals showed that the prevalence of hepatitis
B surface antigen (HBsAg) seropositivity among diabetic
patients was higher than the nondiabetic ones (21.3% vs.
15.53%) (2). Moreover, another study reported that the risk
of HBV infection among diabetic patients was 1.5 times
higher than nondiabetic individuals (9).
Nonetheless, some studies have reported an inverse
relationship between HBV infection and DM. A study on
900 Chinese laborers with no history of DM revealed that
51.6% were positive for hepatitis B surface antibody (HB-
sAb) and 25% were HBsAg positive. The prevalence of DM
among HBsAb-positive patients was lower than the HBsAg-
positive ones (15.7% vs. 26.5%) (10). Given the contradictory
results of previous research, the present study was con-
ducted to evaluate the prevalence and risk factors for type
II DM among patients with HBV infection.
2. Methods
This community-based, cross sectional, descriptive,
correlational study was performed to evaluate the preva-
lence and risk factors for type II DM among patients with
HBV in Esfandiar rural area, Tabas, Iran. This area was se-
lected, as it reportedly has the highest prevalence of HBV in
Iran. All dwellers in this area were recruited through cen-
sus sampling.
We visited the participants at home, explained the
aims of the study, invited them to the study, and asked
them to refer to the infectious diseases research center
of Birjand University of Medical Sciences (Birjand, Iran)
for blood sampling. In the research center, a blood sam-
ple was collected from each individual for serological
and biochemical tests, including triglyceride, cholesterol,
hemoglobin A1c (HbA1c), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), HBsAg, and hepatitis B
core antibody (HBcAb); the necessary data were collected
accordingly.
The data collection tool was a demographic and clin-
ical questionnaire. It included items on the participants’
age, gender, blood pressure, and risk factors for HBV and
type II DM, including blood transfusion, positive family
history of hepatitis, cupping therapy, drug abuse, and
cigarette smoking. The questionnaire was completed for
each participant through face-to-face interviews. Content
validity of the questionnaire was confirmed by 3 faculty
members from Birjand University of Medical Sciences, Bir-
jand, Iran.
Blood samples were sent to a local laboratory, where
a trained laboratory technician analyzed the samples pri-
marily for total HBcAb and liver transaminase. The HBcAb
test was performed using enzyme-linked immunosorbent
assay (ELISA) kits. The remaining sera were transferred
to Eppendorf tubes and stored at -30°C. After primary HB-
cAb testing, HBcAb-positive samples were analyzed for HB-
sAg and HbA1c. HBsAg-positive subjects were considered
as having HBV. On the other hand, individuals with HbA1c
above 6.5, oral antidiabetic medication use, or with blood
sugar above 200 mg/dL were considered diabetic, based on
the American diabetes association criteria for DM diagno-
sis (2).
The collected data were entered into SPSS v. 22.0 and
analyzed using independent sample t test, Chi square test,
and Fisher’s exact test. Data are presented using descrip-
tive statistics, such as percentage, frequency, mean, and
standard deviation.
This study was approved by the institutional review
board and ethics committee of Birjand University of
Medical Sciences, Birjand, Iran (ethical approval code,
IR.BUMS.REC1395.207). Each participant was personally in-
formed about the aim of the study and was asked to pro-
vide an informed consent for participation.
3. Results
This study was conducted on 1245 rural dwellers, aged
36.5 ± 18.5 years (age range, 13 - 96 years). The study sam-
ple included 676 (54.3%) males and 569 (45.7%) females. The
prevalence of type II DM, HBsAg positivity, and HBcAb pos-
itivity among the participants was 7.6% (n, 95), 12.5% (n,
156), and 36.9% (n, 460), respectively. The prevalence of
HBsAg positivity among diabetic and nondiabetic partic-
ipants was 15.8% (15 out of 95) and 12.3% (141 out of 1150),
respectively. The difference between diabetic and nondia-
betic subjects regarding HBsAg positivity was not signifi-
cant (P = 0.32).
The findings revealed that HBsAg-positive and HBsAg-
negative diabetic patients were not significantly different
regarding age, body mass index (BMI), systolic and dias-
tolic blood pressure, ALT, and HbA1c (P > 0.05). However,
the level of AST was significantly higher in HBsAg-positive
diabetic subjects, compared to their HBsAg-negative coun-
terparts (P = 0.01; Table 1). Moreover, the prevalence of
HBsAg positivity among male and nonsmoker diabetic pa-
tients was higher than female and smoker diabetic pa-
tients, respectively (P = 0.02). However, HBsAg positivity
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among diabetic participants had no significant relation-
ship with history of cupping therapy or drug abuse (P >
0.05; Table 2).
Statistical analysis revealed that the mean age, BMI,
systolic and diastolic blood pressure, and waist circum-
ference were significantly higher in diabetic participants,
compared to their nondiabetic counterparts (P < 0.05; Ta-
ble 3). Moreover, DM had a significant relationship with ed-
ucational status, family history of HBV, cigarette smoking,
history of hypertension, and noninjection drug abuse (P <
0.05; Table 3).
4. Discussion
This cross sectional, descriptive, analytical study was
performed on 1245 individuals, who resided in Esfandiar
rural areas, Tabas, Iran. The prevalence of type II DM was
7.6% in the study population (n, 95), and the prevalence of
HBsAg positivity was 12.5% (n, 156). HBsAg positivity was
more prevalent among diabetic patients (15.8%), compared
to the nondiabetic ones (12.3%). Although this difference
was statistically insignificant, it was of clinical importance.
In addition, the prevalence of DM among male HBsAg-
positive participants was significantly higher than their fe-
male counterparts. However, HBsAg positivity among dia-
betic patients had no significant relationship with history
of cupping therapy or drug abuse.
Most earlier studies have reported a higher prevalence
of DM among patients with hepatitis C virus (HCV) infec-
tion. In this regard, a study on patients with chronic liver
disease showed that the prevalence of DM among HCVAb-
positive and HBsAg-positive patients was 21% and 12%, re-
spectively (11). Another study on 400 patients with a defi-
nite diagnosis of DM indicated that 2.5% suffered from HCV
infection, while the prevalence of HCVAb positivity in the
nondiabetic population was 1% (12). In 3 other studies, the
prevalence of DM among patients with hepatitis was esti-
mated at 14.3% (13), 2.2% (14), and 39% (15), respectively.
The association between DM and HCV infection may be
attributed to insulin resistance, caused by the negative ef-
fects of HCV on the function of islet cells. Insulin resis-
tance, in turn, facilitates lipolysis and causes the accumu-
lation of free fatty acids in the liver. When the antioxidant
capacity of the liver is low, increased levels of inflamma-
tory cytokines in response to free fatty acid accumulation
in the liver can impair mitochondrial function and result
in tissue necrosis (16).
Despite the established association of HCV with DM,
previous studies have reported contradictory results re-
garding the association of HBV with DM. In line with the
present findings, most previous studies have reported a di-
rect relationship between DM and HBV infection. In this
regard, a study on 3377 Chinese people showed that HBsAg
positivity was higher among diabetic patients, compared
to the nondiabetic ones (21.3% vs. 15.53%) (2). Another study
revealed that the association between HBsAg positivity and
DM is more evident among Asians than Icelanders (22.5%
vs. 7%) (17).
Moreover, a study on diabetic and nondiabetic individ-
uals, who were referred to a diabetes clinic during 2005
- 2014, revealed that the prevalence of HBV among dia-
betic patients was significantly higher than nondiabetic
patients (13.5% vs. 10%). Therefore, the risk of HBV infection
in the former group was 1.5 times higher than the latter
group (18). Some studies have also confirmed the higher
prevalence of DM among diabetic patients. The prevalence
of DM in HBsAg-positive versus HBsAg-negative individuals
was 13.5% versus 12.5% in Thailand (19), 4.6% versus 4.3% in
Africa (20), 5.1% versus 3.8% in Turkey (11), 20% versus 17.3%
in Nigeria (21), and 3.4% versus 2.2% in China (10, 19, 20).
There are different explanations for the association be-
tween HBV infection and DM. One explanation is related to
the direct effects of HBV on pancreatic lymphocytes, result-
ing in decreased insulin production. The second explana-
tion is that in patients with HBV, protein X reduces the ex-
pression of insulin receptor proteins (22).
The third explanation is HBV-induced B lymphocyte
autoimmunity and subsequent degeneration of insulin-
producing islet cells. The fourth explanation pertains to
the protective or predisposing effects of certain haplotypes
of human leukocyte antigens (e.g., DR2, DR51, and DQB6)
on viral infections (7). Finally, diabetic patients experience
frequent hospitalizations and blood sampling procedures
and are consequently at a greater risk of HBV infection.
On the contrary, some studies have reported no differ-
ence in the prevalence of DM among HBsAg-positive and
HBsAg-negative individuals; a lower prevalence of DM has
been even reported among HBsAg-positive individuals. A
study reported that the prevalence of DM among patients
with positive HBsAg antibody was lower than those with-
out the antibody (36.5% vs. 15.7%) (10). Also, a study on
108 diabetic and 108 nondiabetic subjects showed that DM
prevalence was 3.7% in both groups (22). These contradic-
tions may be due to differences in the study sample, labora-
tory techniques and kits for DM and hepatitis assessments,
geographical spread and prevalence of DM and HBV, and
stage or window period of hepatitis.
Our findings also showed that the major risk factors
for DM among patients with HBV were positive family his-
tory of DM, low educational status, cigarette smoking, his-
tory of hypertension, and noninjection drug abuse. More-
over, the mean age, BMI, waist circumference, AST, ALT,
and HbA1c among HBsAg-positive diabetic patients were
higher than their nondiabetic counterparts.
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Table 1. Numerical Demographic and Clinical Characteristics of HBsAg-Positive and HBsAg-Negative Diabetic Patients
Characteristics All Diabetic Cases (N, 95) HBsAg Test Results
Positive (N, 15) Negative (N, 80) P Value
Age, y 55.4 ± 14.4 57 ± 8.7 55.1 ± 15.2 0.65
Bodymass index, kg/m2 25.6 ± 5.6 25.8 ± 3.6 25.6 ± 5.9 0.89
Systolic blood pressure 12.6 ± 2.2 13.3 ± 2 12.5 ± 1.9 0.2
Diastolic blood pressure 8.1 ± 1 8.4 ± 0.92 8 ± 1.03 0.23
ALT 11.7 ± 5.4 13.8 ± 8 11.3 ± 4.8 0.12
AST 23.2 ± 8.2 28.4 ± 13 22.2 ± 6.8 0.01
HbA1c 7.04 ± 1 6.91 ± 0.58 7.06 ± 1.07 0.61
Table 2. Categorical Demographic and Clinical Characteristics of HBsAg-Positive and HBsAg-Negative Diabetic Patients
Characteristics All Diabetic Cases (N, 95) Diabetic Cases Based onHBsAg Test Results
Positive (N, 15) Negative (N, 80) P Value
Gender P = 0.02
Male 38 (41.1) 10 (26.3) 28 (73.7)
Female 57 (58.9) 5 (8.8) 52 (91.2)
Cigarette smoking P = 0.02
Yes 12 (12.6) 0 (0) 12 (100)
No 83 (87.4) 15 (18.1) 68 (81.9)
Cupping therapy P = 0.08
Yes 20 (21.1) 6 (30) 14 (70)
No 75 (78.9) 9 (12) 66 (88)
Noninjection drug abuse P = 0.11
Yes 24 (25.3) 1 (4.2) 23 (95.8)
No 71 (74.7) 14 (19.7) 57 (80.3)
Previous studies on patients with hepatitis have also
shown significant differences between diabetic and non-
diabetic individuals regarding the mean ALT level (18, 21),
mean age, cirrhosis (23), mean BMI, AST, ALT, HbA1c, choles-
terol, and triglyceride (24). Another study on patients
with HBV showed that diabetic patients had a significantly
higher mean age (47.4 vs. 57 years) and BMI (28.4 vs. 34.5
kg/m2), compared to nondiabetic individuals (25).
In a study on patients with hepatitis in Italy, the hy-
perendemic area for liver disease, mean HbA1c, BMI, AST,
and ALT were significantly higher among diabetic patients,
compared to nondiabetic individuals (26). All these find-
ings confirm that older age, greater BMI, and higher lev-
els of liver enzymes and HbA1c can be risk factors for DM
among patients with HBV. HbA1c, overweight, and obesity
can also cause steatosis, liver tissue injury, and hepatic fi-
brosis, and thereby, accelerate hepatic disease. Steatosis
can also cause insulin resistance and aggravate DM.
4.1. Conclusion
This study suggests that HBV can be a risk factor for
type II DM. Therefore, continuous monitoring and regu-
lar assessment of DM are essential for patients with HBV,
particularly those above 50 years, those with BMI above 25
kg/m2, those with a positive family history of type II DM,
and those with abnormally high levels of AST and ALT.
4.2. Limitations
One limitation of this study is that HBV diagnosis was
established based on HBsAg seropositivity. Given the like-
lihood of occult HBV among the participants, further labo-
ratory studies (e.g., polymerase chain reaction) for HBsAg-
negative individuals can provide more reliable results.
Moreover, this study was conducted on rural dwellers, who
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Table 3. Comparison of Diabetic and Nondiabetic Participants Regarding the Risk Factors for HBV and Type II DM
Risk Factors Diabetic Cases (N, 95) Nondiabetic Cases (N, 1150) P Value
HbA1c 7.04 ± 1 5.64 ± 0.42 P < 0.001
BMI 25.6 ± 5.6 21.9 ± 5.1 P < 0.001
Bodymass index, kg/m2 55.4 ± 14.4 34.9 ± 18.5 P < 0.001
Systolic blood pressure 12.6 ± 2 11.3 ± 1.6 P < 0.001
Diastolic blood pressure 8.1 ± 1 7.3 ± 0.97 P < 0.001
Waist circumference 91.4 ± 13.6 78.8 ± 14.4 P < 0.001
ALT 11.7 ± 5.4 11.2 ± 16.9 P = 0.76
AST 23.2 ± 8.2 22.5 ± 17.9 P = 0.72
Gender P = 0.25
Male 57 (60) 619 (53.8)
Female 38 (40) 531 (46.2)
Educational status P < 0.001
Illiterate 29 (31.2) 131 (12.1)
Primary 56 (60.2) 488 (44.9)
Junior high 5 (5.4) 195 (18)
High school 2 (2.2) 203 (18.7)
University 1 (1.1) 69 (6.4)
Family history of hepatitis P < 0.001
Yes 15 (15.8) 63 (5.5)
No 80 (84.2) 1087 (94.5)
Cigarette smoking P = 0.005
Yes 12 (12.6) 63 (5.5)
No 83 (87.4) 1087 (94.5)
Hypertension P < 0.001
Yes 39 (41.1) 84 (7.3)
No 56 (58.9) 1066 (92.7)
Noninjection drug abuse P < 0.001
Yes 24 (25.3) 89 (7.7)
No 71 (74.7) 1061 (92.3)
are usually more physically active, have healthier eating
behaviors, and are less at risk of DM, compared with ur-
ban dwellers. Finally, factors involved in the high preva-
lence of HBV might have also affected DM development
and prevalence. Further studies are needed to determine
the contributing factors for the high prevalence of HBV in
the study region and to identify HBV genotypes and human
leukocyte antigen typing of HBV.
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